JP2002530353A - ウイルス性出血熱の処置法 - Google Patents

ウイルス性出血熱の処置法

Info

Publication number
JP2002530353A
JP2002530353A JP2000583560A JP2000583560A JP2002530353A JP 2002530353 A JP2002530353 A JP 2002530353A JP 2000583560 A JP2000583560 A JP 2000583560A JP 2000583560 A JP2000583560 A JP 2000583560A JP 2002530353 A JP2002530353 A JP 2002530353A
Authority
JP
Japan
Prior art keywords
protein
hemorrhagic fever
activated protein
administered
fever
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000583560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002530353A5 (https=
Inventor
チャールズ・ジャック・フィッシャー
サウ−チ・ベティ・ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2002530353A publication Critical patent/JP2002530353A/ja
Publication of JP2002530353A5 publication Critical patent/JP2002530353A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000583560A 1998-11-20 1999-11-15 ウイルス性出血熱の処置法 Pending JP2002530353A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10915398P 1998-11-20 1998-11-20
US60/109,153 1998-11-20
PCT/US1999/027074 WO2000030677A1 (en) 1998-11-20 1999-11-15 Method of treating viral hemorrhagic fever

Publications (2)

Publication Number Publication Date
JP2002530353A true JP2002530353A (ja) 2002-09-17
JP2002530353A5 JP2002530353A5 (https=) 2006-12-14

Family

ID=22326085

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000583560A Pending JP2002530353A (ja) 1998-11-20 1999-11-15 ウイルス性出血熱の処置法

Country Status (12)

Country Link
US (2) US6270764B1 (https=)
EP (1) EP1131091B1 (https=)
JP (1) JP2002530353A (https=)
CN (1) CN1326356A (https=)
AT (1) ATE235915T1 (https=)
AU (1) AU2149800A (https=)
BR (1) BR9915460A (https=)
CA (1) CA2351470A1 (https=)
DE (1) DE69906568T2 (https=)
ES (1) ES2195655T3 (https=)
IL (1) IL142220A0 (https=)
WO (1) WO2000030677A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
EA200400548A1 (ru) 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
US7132398B2 (en) 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
EP1729791A2 (en) * 2004-03-17 2006-12-13 Chiron Corporation Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
WO2007092607A2 (en) * 2006-02-09 2007-08-16 Genetech, Inc. Treatment of hemorrhagic viral infections using a tissue factor inhibitor
RU2379034C1 (ru) * 2008-11-17 2010-01-20 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Способ лечения геморрагической лихорадки с почечным синдромом
EP3551198B1 (en) * 2016-12-08 2022-02-02 Cellphire Inc. Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
CA3121200A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
WO2020112963A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
IL322149A (en) 2019-05-03 2025-09-01 Cellphire Inc Materials and methods for manufacturing blood products
CN114450066A (zh) 2019-08-16 2022-05-06 塞尔菲乐有限公司 作为抗血小板剂逆转剂的血栓小体
CA3170196A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
CZ298429B6 (cs) * 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
EP1090130A1 (en) * 1999-04-30 2001-04-11 Eli Lilly And Company Protein c derivatives

Also Published As

Publication number Publication date
CN1326356A (zh) 2001-12-12
US20010028880A1 (en) 2001-10-11
US6270764B1 (en) 2001-08-07
ES2195655T3 (es) 2003-12-01
US6767539B2 (en) 2004-07-27
EP1131091A1 (en) 2001-09-12
DE69906568T2 (de) 2004-02-12
AU2149800A (en) 2000-06-13
DE69906568D1 (de) 2003-05-08
EP1131091B1 (en) 2003-04-02
ATE235915T1 (de) 2003-04-15
WO2000030677A1 (en) 2000-06-02
CA2351470A1 (en) 2000-06-02
BR9915460A (pt) 2001-07-17
IL142220A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
JP3805981B2 (ja) 凝固亢進状態または後天性プロテインｃ欠乏症を処置する方法
US6159468A (en) Activated protein C formulations
US6630137B1 (en) Activated protein C formulations
US6767539B2 (en) Method of treating viral hemorrhagic fever
JP2002527490A (ja) 敗血症を治療する方法
EP1133314B1 (en) Protein c for the treatment of sickle cell disease and thalassemia
US20050143283A1 (en) Activated protein c formulations
JP2002529515A (ja) ヘパリンにより誘発される血小板減少症の処置法
EP1137432B1 (en) Use of protein c for the treatment of thrombocytopenic purpura and hemolytic uremic syndrome
MXPA01005038A (en) Method of treating viral hemorrhagic fever
MXPA01005124A (en) Method of treating sickle cell disease and thalassemia
EP1561469A1 (en) Activated Protein C Formulations
HK1016472B (en) Activated protein c formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061025

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100203

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810